Adamis Pharmaceuticals (ADMP) – Company Press Releases
-
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
-
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
-
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
-
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
-
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
-
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
-
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
-
Adamis Pharmaceuticals Announces Reverse Stock Split
-
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
-
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
-
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
-
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
-
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
-
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
-
Adamis Announces Review of Strategic Alternatives
-
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
-
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
-
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
-
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
-
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
-
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
-
Adamis Pharmaceuticals Issues Letter to Stockholders
-
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
-
Adamis Appoints Vickie Reed to Board of Directors
-
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
-
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
-
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
-
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
-
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
-
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
-
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
-
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
-
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
-
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
-
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
-
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
-
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
-
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
-
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
-
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
-
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
-
Adamis Receives FDA Approval for ZIMHI
-
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
Back to ADMP Stock Lookup
